New hope for frail lung cancer patients: immunotherapy drug tested

NCT ID NCT04108026

Completed Disease control Sponsor: Intergroupe Francophone de Cancerologie Thoracique Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the immunotherapy drug durvalumab in 50 patients with advanced lung cancer who were too weak for standard chemotherapy. The goal was to see if the drug is safe and helps control the disease. Researchers focused on side effects and how well patients responded.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab (an immunotherapy drug)
What this could lead to: If successful, this could offer a treatment option for lung cancer patients who are too frail for standard chemotherapy, potentially improving survival and quality of life.
What could go wrong: This is a small, single-arm Phase 2 trial with only 50 participants, so results may not apply broadly. The drug may cause serious side effects, and there is no comparison group to confirm benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER STAGE IV

Contacts and locations

Locations

AP-HM Hopital Nord

Marseille, France
AP-HP Hopital Tenon - Pneumologie

Paris, 75020, France
Besançon - CHU

Besançon, France
CH

Colmar, France
CHR d'Orléans La Source

Orléans, France
CHRU Grenoble

Grenoble, France
CHRU de Lille

Lille, France
CHU Strasbourg

Strasbourg, France
CHU Toulouse - Pneumologie

Toulouse, France
CHU Tours - Pneumologie

Tours, France
Caen - CHU Côte de Nacre

Caen, 14000, France
Centre Hospitalier - Pneumologie

Le Mans, 72000, France
GRH Mulhouse Sud-Alsace

Mulhouse, France
Hôpital Ambroise Paré - Pneumologie

Boulogne, France
Lyon - URCOT

Pierre-Bénite, France
Montpellier - CHRU

Montpellier, 34295, France
Nancy - Institut de Cancérologie de Lorraine

Nancy, France
Nantes - ICO Site René Gauducheau

Nantes, 44805, France
Paris - APHP Bichat

Paris, France
Paris - Curie

Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.